Our Work
Leading the Industry in Developing Proprietary Psychedelic-Based Therapeutics
Our pipeline is derived from our novel drug discovery platform
PROGRAM1
- DISCOVERY
- PRECLINICAL
- PHASE 1
- PHASE 2
- PHASE 3
- REGISTRATION
Mental Distress in Healthcare Workers2
EMBARK – Psilocybin for mental distress in frontline healthcare workers
PHASE 2
Psychedelic Effects On Brain3
Kernel Flow - Neuroimaging Technology
PHASE 1
Major Depressive Disorder
CYB003 - Deuterated Psilocybin Analog
PRECLINICAL
Alcohol Use Disorder
CYB003 - Deuterated Psilocybin Analog
PRECLINICAL
Anxiety Disorders
CYB004-Deuterated Dimethyltryptamine (DMT)
PRECLINICAL
Neuroinflammation
CYB005-Phenethylamine Derivative
PRECLINICAL
Q1 2022
Completed CYB003
preclinical studies
CYB003 Scientific
Advice meeting with
UK MHRA
Initiated EMBARK
Phase 2 IIT study
Initiated Kernel Flow
feasibility study
Q2 2022
Submitted CYB003 IND filing for Phase 1/2a MDD trial
Announced Preclinical data for CYB004 vs. DMT
Accelerated CYB004 into Phase 1 development through acquisition
Late Q2: preclinical data expected for CYB005
Nominate CYB005 as partnering candidate
Q3 2022
Mid-2022:
Initiate CYB003 Phase 1/2a MDD study
Continue to progress CYB004-E Phase 1 clinical trial
.
Q4 2022
Potential CYB003 interim data readout
- Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Cybin is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocybin and other analogues.
- Phase 2 investigator-initiated study being conducted by Dr. Anthony Back, professor of medicine (oncology) at the UW School of Medicine and co-funded by Cybin.
- Cybin-sponsored Phase 1 feasibility study evaluating Kernel’s Flow Technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
Our Psychedelic Molecules & Program Overview
CYB003: Deuterated Psilocybin Analog
Our lead investigational molecule, CYB003, is derived from psilocybin, which is part of a family of molecules called indolamines that includes more common neurotransmitters, such as serotonin. Psilocybin is dephosphorylated to form its metabolite, psilocin, which can cross the blood-brain-barrier. Given its structural similarity to serotonin, psilocybin can easily activate the serotonin 5-HT2A receptor. CYB003 is a deuterated psilocybin analog designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability for an overall better outcome for patients. CYB003 has the potential to effectively treat major depressive disorder (MDD) and alcohol use disorder (AUD).
Current status: regulatory filing submitted in May 2022 and Phase 1/2a trial initiation expected in mid-2022
CYB004: Deuterated Dimethyltryptamine (DMT)
CYB004 is a deuterated dimethyltryptamine (DMT), which has been shown to exert its psychedelic effects by activating the 5-HT2A receptor. In its natural form, DMT is rapidly metabolized in the body, unstable and not orally bioavailable. Based on preclinical studies, deuterated DMT has the potential to overcome these limitations and provide increased oral and pulmonary bioavailability, faster onset with lower doses, less patient variability, and better dose titration for fewer side effects and longer acting desensitization of the serotonergic receptors. CYB004 has the potential to effectively treat anxiety disorders.
Current status: Conducting Phase 1 in-human study evaluating 50 healthy volunteers who smoke tobacco
CYB005: Discovery-Phase Phenethylamine Derivative
CYB005 is a discovery-phase phenethylamine derivative with the potential to effectively treat neuroinflammation and psychiatric conditions.
Current status: In preclinical development
Patents
Cybin has multiple patent filings covering a wide range of novel psychedelic compounds from different classes, including targeted structural modifications to improve the drug pharmacokinetic characteristics and safety profiles without altering their receptor binding.
These novel drug delivery platform claims are expected to enable administration of the psychedelic drugs with faster onset of action, higher bioavailability by way of bypassing the liver metabolism, and expected to offer more control for better patient experience and optimized therapeutic outcomes.
Cybin was granted a patent by the USPTO for CYB004, its proprietary deuterated DMT molecule, in February 2022. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT, and protects CYB004 drug substance as a putative new chemical entity.
Our Work
Our 3 Pillar Strategy
Novel Drug Discovery Platform
API Modification
Develop new API’s via selective modifications of tryptamine and phenethylamine-based scaffolds specifically to alter their pharmacokinetics without modifying their therapeutic potential.
Modifications involve replacing selective hydrogens with deuterium atoms.
Optimizing unique physicochemical attributes e.g. salts, crystal forms, co-crystals, etc.
Proprietary Drug Delivery Systems
Research and Development
Efficient delivery system that attempts to bypass the liver metabolism with a direct path to the brain providing a faster onset.
Modified-release formulations with the potential to reduce side effects and to control exposure.
Dose control through proprietary device platform.
Delivery systems may be applied to many psychedelic compounds.
Innovative Treatment Regimen
Science Meets Technology
Software-based platform to gather clinical research data from psychedelic treatment.
EMBARK six domain best-practices psychotherapy program designed to provide consistent therapist training and consistent psychotherapy delivery in clinical trials.
Advancing Mental Healthcare Through Evidence Based Therapeutics
CYB001
PHASE IIA & PHASE IIB CLINICAL TRIAL
SUBLINGUAL PSILOCYBIN IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
PHASE IIA
Randomized Parallel Group Open Label BE Study
PSILOCYBIN (PY)
PHASE IIB
Randomized Double Blind Placebo Controlled Safety & Efficacy Study
MDD patients with moderate depression (MADRS score 18-34)
Primary efficacy in 30 days
Patients will be followed for 4 months for safety and efficacy
Duration: approx 12 months
Clinical trial will adhere to ICH and GCP guidelines, with the aim to utilize clinical data in jurisdictions such as USA, Canada and Europe.